SAIC support helps close MNS round

Southern Angels members supported the recent funding round for Leeds-based Microneedle Solutions (‘MNS’), which successfully raised substantial capital to support their next phase of growth, including first-in-human clinical trials to be delivered in collaboration with the NHS this year.

SAIC investor Jan Paul Van Driel congratulated MNS on their round’s  success, which was significantly oversubscribed, adding;

“SAIC members have supported the growth of MNS since their first SEIS round in 2023 and it’s great to see them creating this opportunity to transform the way vaccines and other medicines can be delivered – they now have substantial new capital to help MNS grow into an exciting business with global impact.”

This funding enables MNS to advance Miracus™, our needle-free patch platform, into first-in-human clinical trials, a critical step toward transforming how vaccines and therapeutics are delivered.

As Henry Dunne, CEO of MNS, commented:

“This funding is a real testament to the hard work the team has put in over the last couple of years building and validating the Miracus platform. I am pleased at the breadth and depth of investors joining us in our mission to provide patients, clinicians and industry with better drug-delivery options that improve clinical outcomes and expand global access to medicines.”

For over 200 years, the needle and syringe have remained largely unchanged. At MNS, we’re working to change that by enabling low-cost, needle-free delivery that improves patient experience and global access.